HIV/丙型肝炎病毒合并感染患者中丙型肝炎病毒高病毒载量：基于蛋白酶抑制剂和非蛋白酶抑制剂的高效抗逆转录病毒治疗的不同影响？

High hepatitis C virus viral load in HIV/hepatitis C virus-co-infected patients: a different influence of protease inhibitor and non-protease inhibitor-based HAART?

作者信息

Bani-Sadr Firouzé, Goderel Isabelle, Morand Patrice, Payan Christopher, Lunel Françoise, Pol Stanislas, Perronne Christian, Carrat Fabrice, Cacoub Patrice

机构信息

Groupe Hospitalier Universitaire Est, Université Paris 6, INSERM U707, Paris, France.

出版信息

AIDS. 2007 Jul 31;21(12):1645-8. doi: 10.1097/QAD.0b013e32826fb710.

DOI:10.1097/QAD.0b013e32826fb710

PMID:17630563

Abstract

We examined the possible relationships between hepatitis C virus (HCV) viral load and host factors, viral factors, and anti-HIV therapy in 379 HIV/HCV-co-infected patients. Multiple linear regression analysis identified two independent factors associated with higher HCV viral load, HCV genotype 1 or 4 infection and protease inhibitor-based antiretroviral therapy. Antiretroviral therapy in general was independently associated with lower HCV viral load. This suggests that HCV viral load kinetics could differ according to the choice of HAART regimen.

摘要

我们在379例合并感染人类免疫缺陷病毒（HIV）和丙型肝炎病毒（HCV）的患者中，研究了HCV病毒载量与宿主因素、病毒因素及抗HIV治疗之间的可能关系。多元线性回归分析确定了与较高HCV病毒载量相关的两个独立因素，即HCV 1型或4型感染以及基于蛋白酶抑制剂的抗逆转录病毒治疗。一般来说，抗逆转录病毒治疗与较低的HCV病毒载量独立相关。这表明，根据高效抗逆转录病毒治疗（HAART）方案的选择，HCV病毒载量动力学可能有所不同。